Premarin for Alzheimer's Phase II trial to begin in autumn under auspices of NIA.
PREMARIN FOR ALZHEIMER's PHASE II STUDY TO BEGIN IN LATE AUTUMN in a National Institute on Aging- sponsored trial examining the use of Wyeth-Ayerst's conjugated estrogens product to treat the loss of cognitive function associated with Alzheimer's disease. Under the supervision of project director Ruth Mulnard, University of California-Irvine, the study will test whether estrogen replacement therapy can improve or stabilize cognitive function in hysterectomized, postmenopausal women with dementia.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth